Optimization of the lyophilization process for long-term stability of solid-lipid nanoparticles
- PMID: 22235767
- DOI: 10.3109/03639045.2011.645835
Optimization of the lyophilization process for long-term stability of solid-lipid nanoparticles
Abstract
Objectives: To optimize a lyophilization protocol for solid-lipid nanoparticles (SLNs) loaded with dexamethasone palmitate (Dex-P) and to compare the long-term stability of lyophilized SLNs and aqueous SLN suspensions at two storage conditions.
Materials and methods: The effect of various parameters of the lyophilization process on SLN redispersibility was evaluated. A three month stability study was conducted to compare changes in the particle size and drug loading of lyophilized SLNs with SLNs stored as aqueous suspensions at either 4°C or 25°C/60% relative humidity (RH).
Results and discussion: Of nine possible lyoprotectants tested, sucrose was shown to be the most efficient at achieving SLN redispersibility. Higher freezing temperatures, slower freezing rates, and longer secondary drying times were also shown to be beneficial. Loading of the SLNs with Dex-P led to slightly larger particle size and polydispersity index increases, but both parameters remained within an acceptable range. Drug loading and particle shape were maintained following lyophilization, and no large aggregates were detected. During the stability study, significant growth and drug loss were observed for aqueous SLN suspensions stored at 25°C/60% RH. In comparison, lyophilized SLNs stored at 4°C exhibited a consistent particle size and showed <20% drug loss. Other storage conditions led to intermediate results.
Conclusions: A lyophilization protocol was developed that allowed SLNs to be reconstituted with minimal changes in their physicochemical properties. During a three month period, lyophilized SLNs stored at 4°C exhibited the greatest stability, showing no change in the particle size and a minimal reduction in drug retention.
Similar articles
-
Short- and long-term stability study of lyophilized solid lipid nanoparticles for gene therapy.Eur J Pharm Biopharm. 2009 Feb;71(2):181-9. doi: 10.1016/j.ejpb.2008.09.015. Epub 2008 Oct 7. Eur J Pharm Biopharm. 2009. PMID: 18940256
-
Drug retention and stability of solid lipid nanoparticles containing azidothymidine palmitate after autoclaving, storage and lyophilization.J Microencapsul. 1998 Mar-Apr;15(2):173-84. doi: 10.3109/02652049809006847. J Microencapsul. 1998. PMID: 9532523
-
Solvent injection-lyophilization of tert-butyl alcohol/water cosolvent systems for the preparation of drug-loaded solid lipid nanoparticles.Colloids Surf B Biointerfaces. 2010 Aug 1;79(1):254-61. doi: 10.1016/j.colsurfb.2010.04.005. Epub 2010 Apr 18. Colloids Surf B Biointerfaces. 2010. PMID: 20447810
-
An overview of liposome lyophilization and its future potential.J Control Release. 2010 Mar 19;142(3):299-311. doi: 10.1016/j.jconrel.2009.10.024. Epub 2009 Oct 27. J Control Release. 2010. PMID: 19874861 Review.
-
Solid lipid nanoparticles as drug delivery systems.Methods Find Exp Clin Pharmacol. 2005 Mar;27(2):127-44. doi: 10.1358/mf.2005.27.2.876286. Methods Find Exp Clin Pharmacol. 2005. PMID: 15834465 Review.
Cited by
-
Freeze-drying revolution: unleashing the potential of lyophilization in advancing drug delivery systems.Drug Deliv Transl Res. 2024 May;14(5):1111-1153. doi: 10.1007/s13346-023-01477-7. Epub 2023 Nov 20. Drug Deliv Transl Res. 2024. PMID: 37985541 Review.
-
[FeIIICl(TMPPH2)][FeIIICl4]2: A Stand-Alone Molecular Nanomedicine That Induces High Cytotoxicity by Ferroptosis.Molecules. 2024 May 24;29(11):2495. doi: 10.3390/molecules29112495. Molecules. 2024. PMID: 38893373 Free PMC article.
-
Considerations for mRNA Product Development, Regulation and Deployment Across the Lifecycle.Vaccines (Basel). 2025 Apr 28;13(5):473. doi: 10.3390/vaccines13050473. Vaccines (Basel). 2025. PMID: 40432085 Free PMC article. Review.
-
Long-term storage of lipid-like nanoparticles for mRNA delivery.Bioact Mater. 2020 Mar 18;5(2):358-363. doi: 10.1016/j.bioactmat.2020.03.001. eCollection 2020 Jun. Bioact Mater. 2020. PMID: 32206737 Free PMC article.
-
Development and in vitro evaluations of new decitabine nanocarriers for the treatment of acute myeloid leukemia.Int J Nanomedicine. 2017 Nov 23;12:8427-8442. doi: 10.2147/IJN.S147659. eCollection 2017. Int J Nanomedicine. 2017. PMID: 29200853 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical